A single-center, open-label, study of the persistence of antimicrobial activity of omiganan 1 percent gel vs. chlorhexidine 2 percent for topical skin antisepsis in healthy adult subjects

Trial Profile

A single-center, open-label, study of the persistence of antimicrobial activity of omiganan 1 percent gel vs. chlorhexidine 2 percent for topical skin antisepsis in healthy adult subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Omiganan (Primary) ; Chlorhexidine
  • Indications Bacterial infections; Skin infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Cadence Pharmaceuticals
  • Most Recent Events

    • 27 Jan 2010 Actual number of patients (30) added as reported by ClinicalTrials.gov record.
    • 11 Aug 2008 Planned number of patients changed from 40 to 50 as reported by ClinicalTrials.gov
    • 07 Jun 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top